

T7-308-T025

## Monoclonal Antibody to CD27 PE-Cy™7 conjugated (25 tests)

Clone:	LT27
lsotype:	Mouse IgG2a
Specificity:	The antibody LT27 reacts with CD27 (T14), a 50-55 kDa type I transmembrane glycoprotein (member of the TNF-receptor superfamily) expressed on medullary thymocytes, peripheral T lymphocytes, some B lymphocytes and NK cells. HLDA V; WS Code T T-CD27.01
<b>Regulatory Status:</b>	RUO
Immunogen:	Human peripheral blood lymphocytes
Species Reactivity:	Human
Preparation:	The purified antibody is conjugated with tandem dye PE-Cy™7 under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Storage Buffer:	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage:	The reagent is designed for Flow Cytometry analysis of human blood cells using 4 $\mu$ l reagent / 100 $\mu$ l of whole blood or 10 <sup>6</sup> cells in a suspension. The content of a vial (0.1 ml) is sufficient for 25 tests.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD27 is a transmembrane 55 kDa protein of the nerve growth factor-receptor family, expressed as a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells and a subpopulation of B cells. Activation of T cells via TCR-CD3 complex results in upregulation of CD27 expression on the plasma membrane as well as in the release of its soluble 28-32 kDa form, sCD27, detected in the plasma, urine or spinal fluid. This sCD27 is an important prognostic marker of acute and chronic B cell malignancies. RgpA, a cystein proteinase, although activating T cells through the protease-activated receptors (PARs), degradates CD27 and counteracts T cell activation mediated by CD27 and its ligand CD70.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies References:

\*van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, Hintzen RQ, von dem Borne AE, van Lier RA: Expression and release of CD27 in human B-cell malignancies. Blood. 1993 Dec 1;82(11):3430-6.

\*Molica S, Vitelli G, Levato D, Crispino G, Dell'Olio M, Dattilo A, Matera R, Gandolfo GM, Musto P. CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. Haematologica. 1998 May;83(5):398-402.

\*Kara IO, Sahin B, Gunesacar R: Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. Adv Ther. 2007 Jan-Feb;24(1):29-40.

\*Yun LW, Decarlo AA, Hunter N: Blockade of protease-activated receptors on T cells correlates with altered proteolysis of CD27 by gingipains of Porphyromonas gingivalis. Clin Exp Immunol. 2007 Nov;150(2):217-29.

\*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995). \*Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund-Johansen F, Kalina T: High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016 Apr;15(4):1246-61.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

Cy<sup>™</sup> and CyDye<sup>™</sup> are registered trademarks of GE Healthcare.

For laboratory research only, not for drug, diagnostic or other use.